Merck (NYSE: MRK) recently released its first-quarter results, surpassing Wall Street's expectations for both revenue and earnings. The company reported revenue of $15.53 billion and adjusted earnings per share of $2.22, exceeding consensus estimates of $15.31 billion and $
Merck is a New Jersey-based multinational biopharmaceutical company that develops and commercializes novel therapeutics and vaccines for the treatment of a range of diseases.